-
The IRd regimen helps patients with cytogenetic high-risk MM to achieve lasting remission, with 1q21 amplification case analysis
Time of Update: 2022-10-20
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally, often in old age. Patients with MM with 1q21 amplification tend to have a poor prognosis. Ixazomib-bas
-
Asia vs West, gastric cancer survival data PK
Time of Update: 2022-10-20
*For medical professionals only, meta-analysis reveals similarities and differences in survival data for gastric cancer patients in Asia and the West. Stomach cancer and gastroesophageal adenocarcinom
-
Express HPV-positive refractory tumor patients have improved their survival by more than 4 times, and the results of phase 2 clinical studies of triple therapy are positive
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editor recently, PDS Biotechnology has published interim data from an expanded Phase 2 clinical trial of an investigational triple therapy for advanced human papillomavirus (HPV)-positive cancer, including its lead drug candidate, PDS0101.
-
JCO (IF=51) Wang Jie's team at the Chinese Academy of Medical Sciences has discovered a safe and effective new treatment for non-small cell lung cancer
Time of Update: 2022-10-20
Assessment of PFS curves for two therapies in untreated populations (Figure from Journal of Clinical Oncology) In the final PFS analysis, PFS in the Torpalimab monoclonal antibody group was significantly longer than in the placebo group (median PFS 8.
-
When advanced breast cancer is in remission, which treatment works?
Time of Update: 2022-10-20
Results of PET-CT imaging before the first round of treatmentIn January 2019, after a few months of overall treatment, tests revealed that all of the patient's tumors had disappeared, doctors speculated that chemotherapy and targeted drugs worked, and it was unclear what role the cannabinoids and psilocybin played.
-
Express mRNA Cancer Vaccine in combination with Keytruda! Moderna has teamed up with Merck to target melanoma
Time of Update: 2022-10-20
▎WuXi AppTec content team editorMSD and Moderna today jointly announced that Merck has selected to jointly develop and commercialize the individualized cancer vaccine (PCV) mRNA-4157/V940 with Moderna under an existing collaboration and licensing agreement between the two companies.
-
Case sharing | exploration of the efficacy and safety of albumin paclitaxel + apatinib in the third-line treatment of SCLC and above
Time of Update: 2022-10-20
6%) 。 A phase II prospective clinical study reported by ASCO in 2022 explored the efficacy and safety of albumin paclitaxel in the first-line treatment of extensive-stage small cell lung cancer, and the results showed that the ORR of carrelizumab combined with albumin-bound paclitaxel and carboplatin as the first-line treatment of ES-SCLC was as high as 81.
-
Open up horizons and overview the prospects of ASCT - CSCO Autologous Transplantation Working Group 2022 Tour - Myeloma and Leukemia Special Session (Beijing Station) was a complete success
Time of Update: 2022-10-20
On September 28, 2022, hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee, CSCO Leukemia Expert Committee, CSCO Autologous Hematopoietic Stem Cell Transplantatio
-
Liu Yong's team at Xiangya Hospital of Central South University and others have discovered a potential mechanism to enhance tumor vaccine response
Time of Update: 2022-10-20
On October 13, 2022, Liu Yong's team at Xiangya Hospital of Central South University and Zhang Nu's team at the University of Texas published a research paper entitled "TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine" in Nature Communications。 The study revealed a link between TRM and stem cell-like T cells,which inhibits the migration and effector differentiation of stem cell-like T cells, resulting in weakened anti-tumor immunity.
-
Professor Lin Yanjuan: Standing out, XPO1 inhibitors may bring new opportunities for the treatment of MDS patients
Time of Update: 2022-10-20
Eltanexor is a second-generation SINE compound with lower blood-brain barrier penetration and a wider therapeutic window than the first-generation, so it is better tolerated, can achieve higher frequency dosing and higher doses, longer exposure, and is intended to be developed for the treatment of patients with MDS above risk in IPSS-R who have failed HMA therapy。 At the 2021 ASCO Annual Meeting, the latest data from this study were presented.
-
Express The world's first off-the-shelf T-cell therapy is expected to come out! Lymphoma therapy is recommended for marketing in the European Union
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorAtara Biotherapeutics and Pierre Fabre today announced that their off-the-shelf T-cell immunotherapy Ebvallo (tabelecleucel) has been approved by the European Union Committee for Human Medicines (CHMP) for the treatment of post-transplant lymphoproliferative diseases (EBV+PTLD) associated with Epstein-Barr virus (EBV).
-
Clinically necessary PD-1/PD-L1 monoclonal antibody consensus for clinical application in urogenital tumors
Time of Update: 2022-10-20
Therefore, the Urology Health Promotion Branch of the China Medical Promotion Association and the Urology Professional Committee of the Chinese Research Hospital Association formulated this consensus on diagnosis and treatment safety, hoping to escort the clinical application of immunotherapy in the population of urogenital tumors 。 The consensus focuses on the guarantee of conditions, patient management, selection of the indicated population, efficacy evaluation, monitoring and management of related adverse reactions, and the treatment of complications/unexpected events.
-
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Time of Update: 2022-10-20
Neutrophil-targeted tumor therapy mechanismMechanism (I): Blocks the immune checkpoint of neutrophil (PD1)/PD-L1Targeting PD1/PDL1 is an effective immunotherapy for a variety of cancers, and it can also be used as an effective strategy for targeting TAN.
-
Professor Baili: The FRESCO-2 study shines ESMO, and the status of fruquintinib as the third-line standard treatment for advanced bowel cancer is unshakable
Time of Update: 2022-10-20
Create brilliance again: looking forward to fruquintinib "going abroad and going to the world"From FRESCO research to FRESCO-2 research, fruquintinib, a small molecule anti-angiogenesis-targeted drug independently developed in China, has reached the international top stage, fully verifying the consistent efficacy and safety of fruquintinib in the treatment of advanced bowel cancer patients of different races and regions around the world, indicating that the quality of fruquintinib research data is reliable and the results are reproducible.
-
【JNCI】Sun Yat-sen University led an international multi-center collaboration to develop molecular markers for early colorectal cancer risk prediction
Time of Update: 2022-10-20
DNA methylation profiles of CpG-deficient regions associated with colorectal cancer recurrenceAccurate forecasting 03 03 Based on these findings, the team used machine learning methods to construct MePEC typing, then used QASM technology to achieve rapid, flexible and economical detection, and finally multi-national scholars worked together to complete the application and verification: to achieve accurate prediction of high recurrence risk in patients with early colorectal cancer.
-
This gene is mutated in more than 50% of cancers! One article to understand the different strategies to overcome it
Time of Update: 2022-10-20
Since most TP53 gene mutations cause p53 inactivation, the use of gene therapy to express p53 with normal function is also an important research and development direction to restore p53 function.
-
The latest data: China's liver cancer cases account for 45.3% of the world! How to prevent liver cancer?
Time of Update: 2022-10-20
Electronic Journal of Comprehensive Oncology, 2022, 8(3): 31-63 Guide Q&A mini-sessionFrom now on, the clinical guideline APP will launch a guide Q&A activity every Tuesday, Thursday and Saturday!Participate in the Q&A activity to have a chance to get rewards~The event entrances are as follows:Secondary preventiontargets people with chronic liver disease, controlling related causes and risk factors and screening and monitoring according to risk stratification to reduce or delay the occurrence of liver cancer.
-
Professor Qin Shukui: Pembrolizumab has been approved as a second-line treatment for advanced liver cancer, providing a new preferred drug for liver cancer patients in China
Time of Update: 2022-10-20
China is a country with a high incidence of primary liver cancer, with about 410,000 new liver cancer patients and about 390,000 deaths in 2020, the main type of which is hepatocellular carcinoma (HCC
-
Is the gold standard for colorectal cancer screening or subverted?
Time of Update: 2022-10-20
High-risk groups should start screening after the age of 40, and the method is not limited, and the key is to investigateWritten by | Yan XiaoliuSource | "Medical Community" public number"The clinical view is that for the general population, colonoscopy every 10 years may be able to 'eliminate' colorectal cancer.
-
Express significantly prolongs overall survival for patients with metastatic breast cancer! Gilead ADC is eligible for priority review by the U.S. FDA
Time of Update: 2022-10-20
S. FDA has accepted a Supplemental Biologics License Application (sBLA) for its antibody-conjugate drug Trodelvy (sacituzumab govitecan) for the treatment of patients with HR-positive/HER2-negative metastatic breast cancer who have received multiple upfront treatments.
